Comparison of intraperitoneal anti-adhesive polysaccharides derived from Phellinus mushrooms in a rat peritonitis model.
OBJECTIVE
To assess the adhesion- and abscess-reducing capacities of various concentrations of polysaccharides derived from fungus, Phellinus gilvus (PG) or Phellinus linteus (PL) in a rat peritonitis model.


METHODS
In 96 SD rats, experimental peritonitis was induced using the cecal ligation and puncture model (CLP). Rats were randomly assigned to 8 groups; Ringer's lactate solution (RL group), hyaluronic acid (HA group), 0.025%, 0.25%, and 0.5% polysaccharides from PG (PG0.025, 0.25, and 0.5 groups), and PL (PL0.025, 0.25, and 0.5 groups). Adhesions and abscesses were noted at 7 d after CLP. RT-PCR assay was performed to assess the cecal tissue.


RESULTS
Adhesion formation was significantly reduced in PG0.25, 0.5, PL0.25, 0.5, and HA groups (2.5+/-0.7, 2.4+/-0.7, 3.8+/-1.0, 3.6+/-0.8, and 2.7+/-1.1, P<0.05). The incidence of abscesses was significantly reduced in all treated groups compared to RL group (58%, P<0.05). The urokinase-type plasminogen activator (uPA) gene expression was greatly up-regulated by increasing the concentration of polysaccharides. The urokinase-type plasminogen activator receptor (uPAR) and tumor necrosis factor (TNF)-alpha mRNA were highly expressed in PG0.25, 0.5, PL0.25, and 0.5 groups.


CONCLUSIONS
We concluded that 0.5% polysaccharide derived from PG and PL was the optimal concentration in preventing adhesion and abscess formation and may act by modulating activity of uPA and TNF-alpha in a rat peritonitis model.
Bae
Jae-Sung
JS
Department of Surgery, College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, Republic of Korea.
Jang
Kwang-Ho
KH
Jin
Hee-Kyung
HK
D000038:Abscess / Q000188:drug therapy / Q000473:pathology; D000363:Agaricales / Q000737:chemistry* / Q000145:classification; D000818:Animals; D001835:Body Weight; D004195:Disease Models, Animal; D007274:Injections, Intraperitoneal; D008297:Male; D010538:Peritonitis / Q000188:drug therapy* / Q000473:pathology; D011134:Polysaccharides / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011956:Receptors, Cell Surface / Q000235:genetics; D055293:Receptors, Urokinase Plasminogen Activator; D000267:Tissue Adhesions / Q000188:drug therapy / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics
C524900:Plaur protein, rat; D011134:Polysaccharides; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D014409:Tumor Necrosis Factor-alpha; D014568:Urokinase-Type Plasminogen Activator